Medigene AG (MDG1) - Total Assets
Based on the latest financial reports, Medigene AG (MDG1) holds total assets worth €28.81 Million EUR (≈ $33.68 Million USD) as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medigene AG - Total Assets Trend (2006–2023)
This chart illustrates how Medigene AG's total assets have evolved over time, based on quarterly financial data. Also see Medigene AG (MDG1) market capitalisation for the company's overall valuation and market capitalisation.
Medigene AG - Asset Composition Analysis
Current Asset Composition (December 2023)
Medigene AG's total assets of €28.81 Million consist of 57.2% current assets and 42.8% non-current assets. Review Medigene AG (MDG1) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 27.4% |
| Accounts Receivable | €416.00K | 1.3% |
| Inventory | €1.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €9.85 Million | 31.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2006–2023)
This chart illustrates how Medigene AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See MDG1 live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medigene AG's current assets represent 57.2% of total assets in 2023, an increase from 46.1% in 2006.
- Cash Position: Cash and equivalents constituted 27.4% of total assets in 2023, down from 42.3% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 31.1% of total assets.
Medigene AG Competitors by Total Assets
Key competitors of Medigene AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Medigene AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 4.74 | 6.04 |
| Quick Ratio | 2.39 | 3.38 | 6.10 |
| Cash Ratio | 0.00 | 2.81 | 0.00 |
| Working Capital | €9.10 Million | €22.03 Million | €58.12 Million |
Medigene AG - Advanced Valuation Insights
This section examines the relationship between Medigene AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.10 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -38.6% |
| Total Assets | €31.72 Million |
| Market Capitalization | $1.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medigene AG's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Medigene AG's assets decreased by 38.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Medigene AG (2006–2023)
The table below shows the annual total assets of Medigene AG from 2006 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €31.72 Million ≈ $37.08 Million |
-38.63% |
| 2022-12-31 | €51.68 Million ≈ $60.42 Million |
-13.10% |
| 2021-12-31 | €59.47 Million ≈ $69.53 Million |
-20.44% |
| 2020-12-31 | €74.75 Million ≈ $87.39 Million |
-31.56% |
| 2019-12-31 | €109.22 Million ≈ $127.68 Million |
-15.72% |
| 2018-12-31 | €129.59 Million ≈ $151.50 Million |
+15.77% |
| 2017-12-31 | €111.94 Million ≈ $130.87 Million |
+0.20% |
| 2016-12-31 | €111.72 Million ≈ $130.61 Million |
-1.60% |
| 2015-12-31 | €113.53 Million ≈ $132.73 Million |
+59.27% |
| 2014-12-31 | €71.28 Million ≈ $83.34 Million |
+35.38% |
| 2013-12-31 | €52.66 Million ≈ $61.56 Million |
-14.04% |
| 2012-12-31 | €61.26 Million ≈ $71.61 Million |
+14.94% |
| 2011-12-31 | €53.29 Million ≈ $62.30 Million |
-8.43% |
| 2010-12-31 | €58.20 Million ≈ $68.04 Million |
-11.45% |
| 2009-12-31 | €65.72 Million ≈ $76.84 Million |
-18.61% |
| 2008-12-31 | €80.75 Million ≈ $94.40 Million |
-29.74% |
| 2007-12-31 | €114.93 Million ≈ $134.36 Million |
-7.42% |
| 2006-12-31 | €124.14 Million ≈ $145.13 Million |
-- |
About Medigene AG
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develop… Read more